Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.

Abstract

OBJECTIVE:

To investigate the reciprocal inhibitory effects of hepatitis B virus (HBV)/hepatitis C virus (HCV)/hepatitis D virus (HDV) infections in naive and previously antiretroviral-experienced HIV-positive patients.

DESIGN:

This retrospective study involved 72 consecutive patients of the Italian Cohort Naive Antiretroviral cohort: 21 coinfected with HBV/HCV (group 1BC), 18 infected with HBV (group 2B), and 33 infected with HCV (group 3C).

METHODS:

Viral interference between HBV and HCV was assessed by means of the qualitative detection, quantification, and genotyping of each virus; HDV infection was assessed by means of genomic amplification.

RESULTS:

Univariate analysis showed that HBV DNA was less frequently detected in group 1BC than in group 2B (16 of 21 vs 18 of 18; P = 0.02), their HBV load was significantly lower (median 3.9 vs 5.4 log10 HBV DNA copies/mL; P = 0.002), and they more frequently carried HBV genotype D (12 of 13 vs 4 of 11; P = 0.0071). HCV RNA was less frequently detected in group 1BC than in group 3C (12 of 21 vs 33 of 33; P < 0.0001), and HDV RNA was more frequently detected in group 1BC than in group 2B (9 of 21 vs 2 of 18; P = 0.028). Multivariate analysis of the HBV-infected subjects showed that the risk of HCV coinfection was associated with older age [relative risk 0.28, 95% confidence interval (CI): 0.09 to 0.90; P = 0.033 for every 10 years older] and intravenous drug use (relative risk 73, 95% CI: 2.4 to >999.999; P = 0.013). The only predictor of HBV coinfection in HCV-infected individuals was a lower HCV load (relative risk 0.30, 95% CI: 0.11 to 0.79 for every additional log10 HCV RNA; P = 0.015).

CONCLUSION:

HBV and HCV showed alternative dominant replication in the I.Co.N.A. cohort, with HBV having a more unfavorable effect on HCV replication.

• Authors: Giulia Morsica, Sabrina Bagaglio, Paola Cicconi, Maria R Capobianchi, Giampietro Pellizzer, Pietro Caramello, Anna Orani, Cristina Moioli, Giuliano Rizzardini, Caterina Uberti-Foppa, Massimo Puoti, Antonella D'Arminio Monforte, Hepa I.C.o.N.A the Icona Foundation Study Groups
• Journal: Journal of acquired immune deficiency syndromes (1999) (J Acquir Immune Defic Syndr) Vol. 51 Issue 5 Pg. 574-81 (Aug 15 2009) ISSN: 1525-4135 [Print] United States
• PMID: 19590432 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• DNA Primers
• DNA, Viral
• RNA, Viral

Topics

• Adult
• Anti-HIV Agents (therapeutic use)
• Base Sequence
• Cohort Studies
• DNA Primers (genetics)
• DNA, Viral (blood)
• Female
• HIV Infections (complications, drug therapy, virology)
• Hepacivirus (genetics)
• Hepatitis B (complications, virology)
• Hepatitis B virus (genetics)
• Hepatitis C (complications, virology)
• Hepatitis D (complications, virology)
• Hepatitis Delta Virus (genetics)
• Humans
• Italy
• Male
• Mutation
• RNA, Viral (blood, genetics)
• Retrospective Studies
• Risk Factors
• Viral Interference